Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ZYN002

Small molecule · developed by Harmony Biosciences Management

Phase 3 Most advanced trial (none active)
HRMY Developer
1 Registered trials

What is ZYN002?

ZYN002 is a pharmaceutically manufactured cannabidiol formulated as a clear transdermal gel applied to the skin. It is studied in Fragile X Syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Harmony Biosciences Management, Inc. (HRMY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04977986 Phase 3 Fragile X Syndrome Completed HRMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fragile X SyndromeFragile X Syndrome (FXS)

More from Harmony Biosciences Management

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HRMY page.

Follow HRMY, the company behind ZYN002

See HRMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HRMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.